By vgreene, 15 July, 2020 Study considerations: retrospective, small sample size; imbalanced baseline characteristics; selection bias; propensity score inverse probability weighting; missing data; protocols not standardized
By vgreene, 15 July, 2020 Adjusted analysis: TCZ assoc w/ lower risk of death (hazard ratio 0.55, 95% CI 0.33-0.9) and 28-day case fatality rate (18% vs 36%) and improved status; TCZ assoc w/ more superinfections (54% vs 26%), though no significant difference in 28-day case fatali
By vgreene, 15 July, 2020 Retrospective cohort study; 154 hospitalized pts (median age 58y) w/ severe COVID-19 not eligible for clinical trial enrollment requiring mech vent received TCZ 8 mg/kg x1 (max 800 mg) w/ SOC (n=78) or SOC alone (n=76); SOC incl HCQ or RDV, w/ or w/o CS;
By vgreene, 15 July, 2020 Proposed mechanism: reduces inflammatory response by selectively modulating T-cell activation
By vgreene, 15 July, 2020 Table Example - Emetic potential of parenteral chemo agents: <b>High:</b> >90% risk; <b>Mod:</b> >30%-90% risk; <b>Low:</b> 10%-30% risk; <b>Minimal:</b> <10% risk
By vgreene, 15 July, 2020 Table Example - Emetic potential of parenteral chemo agents: <b>High:</b> >90% risk; <b>Mod:</b> >30%-90% risk; <b>Low:</b> 10%-30% risk; <b>Minimal:</b> <10% risk